{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "11096068", "DateCompleted": {"Year": "2001", "Month": "06", "Day": "28"}, "DateRevised": {"Year": "2021", "Month": "12", "Day": "03"}, "Article": {"ArticleDate": [{"Year": "2000", "Month": "11", "Day": "28"}], "Language": ["eng"], "ELocationID": [], "Journal": {"ISSN": "0021-9258", "JournalIssue": {"Volume": "276", "Issue": "7", "PubDate": {"Year": "2001", "Month": "Feb", "Day": "16"}}, "Title": "The Journal of biological chemistry", "ISOAbbreviation": "J Biol Chem"}, "ArticleTitle": "The plant isoflavenoid genistein activates p53 and Chk2 in an ATM-dependent manner.", "Pagination": {"StartPage": "4828", "EndPage": "4833", "MedlinePgn": "4828-33"}, "Abstract": {"AbstractText": ["Genistein is an isoflavenoid that is abundant in soy beans. Genistein has been reported to have a wide range of biological activities and to play a role in the diminished incidence of breast cancer in populations that consume a soy-rich diet. Genistein was originally identified as an inhibitor of tyrosine kinases; however, it also inhibits topoisomerase II by stabilizing the covalent DNA cleavage complex, an event predicted to cause DNA damage. The topoisomerase II inhibitor etoposide acts in a similar manner. Here we show that genistein induces the up-regulation of p53 protein, phosphorylation of p53 at serine 15, activation of the sequence-specific DNA binding properties of p53, and phosphorylation of the hCds1/Chk2 protein kinase at threonine 68. Phosphorylation and activation of p53 and phosphorylation of Chk2 were not observed in ATM-deficient cells. In contrast, the topoisomerase II inhibitor etoposide induced phosphorylation of p53 and Chk2 in ATM-positive and ATM-deficient cells. In addition, genistein-treated ATM-deficient cells were significantly more susceptible to genistein-induced killing than were ATM-positive cells. Together our data suggest that ATM is required for activation of a DNA damage-induced pathway that activates p53 and Chk2 in response to genistein."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biological Sciences, University of Calgary, Calgary, Alberta T2N 1N4, Canada."}], "Identifier": [], "LastName": "Ye", "ForeName": "R", "Initials": "R"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Bodero", "ForeName": "A", "Initials": "A"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Zhou", "ForeName": "B B", "Initials": "BB"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Khanna", "ForeName": "K K", "Initials": "KK"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Lavin", "ForeName": "M F", "Initials": "MF"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Lees-Miller", "ForeName": "S P", "Initials": "SP"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "J Biol Chem", "NlmUniqueID": "2985121R", "ISSNLinking": "0021-9258"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Androstadienes"}, {"RegistryNumber": "0", "NameOfSubstance": "Benzoquinones"}, {"RegistryNumber": "0", "NameOfSubstance": "Cell Cycle Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "DNA-Binding Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Enzyme Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Lactams, Macrocyclic"}, {"RegistryNumber": "0", "NameOfSubstance": "Quinones"}, {"RegistryNumber": "0", "NameOfSubstance": "Topoisomerase II Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Suppressor Protein p53"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Suppressor Proteins"}, {"RegistryNumber": "1W306TDA6S", "NameOfSubstance": "Rifabutin"}, {"RegistryNumber": "3G6A5W338E", "NameOfSubstance": "Caffeine"}, {"RegistryNumber": "6PLQ3CP4P3", "NameOfSubstance": "Etoposide"}, {"RegistryNumber": "70563-58-5", "NameOfSubstance": "herbimycin"}, {"RegistryNumber": "DH2M523P0H", "NameOfSubstance": "Genistein"}, {"RegistryNumber": "EC 2.7.-", "NameOfSubstance": "Protein Kinases"}, {"RegistryNumber": "EC 2.7.1.11", "NameOfSubstance": "Checkpoint Kinase 2"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "Protein-Tyrosine Kinases"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "ATM protein, human"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Ataxia Telangiectasia Mutated Proteins"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "CHEK2 protein, human"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Protein Serine-Threonine Kinases"}, {"RegistryNumber": "XVA4O219QW", "NameOfSubstance": "Wortmannin"}], "MeshHeadingList": [{"QualifierName": ["pharmacology"], "DescriptorName": "Androstadienes"}, {"QualifierName": [], "DescriptorName": "Ataxia Telangiectasia Mutated Proteins"}, {"QualifierName": [], "DescriptorName": "Benzoquinones"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Caffeine"}, {"QualifierName": [], "DescriptorName": "Cell Cycle Proteins"}, {"QualifierName": [], "DescriptorName": "Cell Line"}, {"QualifierName": [], "DescriptorName": "Checkpoint Kinase 2"}, {"QualifierName": [], "DescriptorName": "DNA Fragmentation"}, {"QualifierName": [], "DescriptorName": "DNA-Binding Proteins"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Enzyme Inhibitors"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Etoposide"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Genistein"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Lactams, Macrocyclic"}, {"QualifierName": [], "DescriptorName": "Mutation"}, {"QualifierName": [], "DescriptorName": "Phosphorylation"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["metabolism"], "DescriptorName": "Protein Kinases"}, {"QualifierName": ["genetics", "physiology"], "DescriptorName": "Protein Serine-Threonine Kinases"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Protein-Tyrosine Kinases"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Quinones"}, {"QualifierName": ["analogs & derivatives"], "DescriptorName": "Rifabutin"}, {"QualifierName": [], "DescriptorName": "Topoisomerase II Inhibitors"}, {"QualifierName": ["metabolism"], "DescriptorName": "Tumor Suppressor Protein p53"}, {"QualifierName": [], "DescriptorName": "Tumor Suppressor Proteins"}, {"QualifierName": [], "DescriptorName": "Wortmannin"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2000", "Month": "11", "Day": "30"}, {"Year": "2001", "Month": "6", "Day": "29", "Hour": "10", "Minute": "1"}, {"Year": "2000", "Month": "11", "Day": "30", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["11096068", "10.1074/jbc.M004894200", "S0021-9258(18)46281-3"]}}], "PubmedBookArticle": []}